DE102011118022B4 - Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung - Google Patents

Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung Download PDF

Info

Publication number
DE102011118022B4
DE102011118022B4 DE102011118022.6A DE102011118022A DE102011118022B4 DE 102011118022 B4 DE102011118022 B4 DE 102011118022B4 DE 102011118022 A DE102011118022 A DE 102011118022A DE 102011118022 B4 DE102011118022 B4 DE 102011118022B4
Authority
DE
Germany
Prior art keywords
antibody
seq
psca
antibodies
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE102011118022.6A
Other languages
German (de)
English (en)
Other versions
DE102011118022A1 (de
Inventor
Michael Bachmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avencell Europe GmbH
Original Assignee
Gemoab Monoclonals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE102011118022.6A priority Critical patent/DE102011118022B4/de
Application filed by Gemoab Monoclonals GmbH filed Critical Gemoab Monoclonals GmbH
Priority to EP12729996.4A priority patent/EP2726507B1/de
Priority to HUE12729996A priority patent/HUE042008T2/hu
Priority to AU2012277784A priority patent/AU2012277784B2/en
Priority to ES12729996T priority patent/ES2711978T3/es
Priority to SI201231523T priority patent/SI2726507T1/sl
Priority to JP2014517736A priority patent/JP2014528696A/ja
Priority to ES18207370T priority patent/ES2989975T3/es
Priority to HRP20190289TT priority patent/HRP20190289T1/hr
Priority to US14/129,933 priority patent/US9200078B2/en
Priority to RS20190218A priority patent/RS58448B1/sr
Priority to DK12729996.4T priority patent/DK2726507T3/en
Priority to EP18207370.0A priority patent/EP3505536B1/de
Priority to PT12729996T priority patent/PT2726507T/pt
Priority to PCT/EP2012/062716 priority patent/WO2013001065A1/de
Priority to TR2019/01991T priority patent/TR201901991T4/tr
Priority to SM20190085T priority patent/SMT201900085T1/it
Priority to PL12729996T priority patent/PL2726507T3/pl
Priority to LTEP12729996.4T priority patent/LT2726507T/lt
Publication of DE102011118022A1 publication Critical patent/DE102011118022A1/de
Priority to JP2017002983A priority patent/JP6549622B2/ja
Application granted granted Critical
Publication of DE102011118022B4 publication Critical patent/DE102011118022B4/de
Priority to CY20191100176T priority patent/CY1121249T1/el
Priority to JP2019117977A priority patent/JP6886491B2/ja
Priority to JP2021081553A priority patent/JP7341185B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE102011118022.6A 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung Expired - Fee Related DE102011118022B4 (de)

Priority Applications (23)

Application Number Priority Date Filing Date Title
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
PT12729996T PT2726507T (pt) 2011-06-30 2012-06-29 Anticorpos contra antigéneos celulares especificos da próstata e uso dos mesmos
AU2012277784A AU2012277784B2 (en) 2011-06-30 2012-06-29 Antibodies against prostate-specific stem cell antigen and use thereof
ES12729996T ES2711978T3 (es) 2011-06-30 2012-06-29 Anticuerpos contra el antígeno de células madre específico de la próstata y su uso
SI201231523T SI2726507T1 (sl) 2011-06-30 2012-06-29 Protitelesa proti antigenu prostatno specifičnih matičnih celic in njihova uporaba
JP2014517736A JP2014528696A (ja) 2011-06-30 2012-06-29 前立腺特異幹細胞抗原に対する抗体およびその使用
ES18207370T ES2989975T3 (es) 2011-06-30 2012-06-29 Anticuerpos contra el antígeno de células madre específico de la próstata y su uso
HRP20190289TT HRP20190289T1 (hr) 2011-06-30 2012-06-29 Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba
US14/129,933 US9200078B2 (en) 2011-06-30 2012-06-29 Antibodies against prostate-specific stem cell antigen and use thereof
HUE12729996A HUE042008T2 (hu) 2011-06-30 2012-06-29 Prosztataspecifikus õssejt antigén elleni antitestek és alkalmazásuk
DK12729996.4T DK2726507T3 (en) 2011-06-30 2012-06-29 ANTIBODY AGAINST THE PROSTATE-SPECIFIC STEM CELL ANTIGEN AND ITS USE
TR2019/01991T TR201901991T4 (tr) 2011-06-30 2012-06-29 Prostat spesifik kök hücre antijenine karşı antikor ve bunun kullanımı.
EP12729996.4A EP2726507B1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung
PCT/EP2012/062716 WO2013001065A1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung
EP18207370.0A EP3505536B1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung
SM20190085T SMT201900085T1 (it) 2011-06-30 2012-06-29 Anticorpi contro l'antigene delle cellule staminali prostatiche e suo uso
PL12729996T PL2726507T3 (pl) 2011-06-30 2012-06-29 Przeciwciała przeciwko antygenowi komórek macierzystych swoistemu dla gruczołu krokowego i ich zastosowanie
LTEP12729996.4T LT2726507T (lt) 2011-06-30 2012-06-29 Antikūnai, atpažįstantys prostatai specifinį kamieninių ląstelių antigeną, ir jų panaudojimas
RS20190218A RS58448B1 (sr) 2011-06-30 2012-06-29 Antitela protiv antigena matičnih ćelija specifičan za prostatu i njihova upotreba
JP2017002983A JP6549622B2 (ja) 2011-06-30 2017-01-12 前立腺特異幹細胞抗原に対する抗体およびその使用
CY20191100176T CY1121249T1 (el) 2011-06-30 2019-02-11 Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτου
JP2019117977A JP6886491B2 (ja) 2011-06-30 2019-06-26 前立腺特異幹細胞抗原に対する抗体およびその使用
JP2021081553A JP7341185B2 (ja) 2011-06-30 2021-05-13 前立腺特異幹細胞抗原に対する抗体およびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Publications (2)

Publication Number Publication Date
DE102011118022A1 DE102011118022A1 (de) 2013-01-03
DE102011118022B4 true DE102011118022B4 (de) 2018-01-18

Family

ID=46384405

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102011118022.6A Expired - Fee Related DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Country Status (18)

Country Link
US (1) US9200078B2 (enExample)
EP (2) EP3505536B1 (enExample)
JP (4) JP2014528696A (enExample)
AU (1) AU2012277784B2 (enExample)
CY (1) CY1121249T1 (enExample)
DE (1) DE102011118022B4 (enExample)
DK (1) DK2726507T3 (enExample)
ES (2) ES2711978T3 (enExample)
HR (1) HRP20190289T1 (enExample)
HU (1) HUE042008T2 (enExample)
LT (1) LT2726507T (enExample)
PL (1) PL2726507T3 (enExample)
PT (1) PT2726507T (enExample)
RS (1) RS58448B1 (enExample)
SI (1) SI2726507T1 (enExample)
SM (1) SMT201900085T1 (enExample)
TR (1) TR201901991T4 (enExample)
WO (1) WO2013001065A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
IL268554B2 (en) 2017-02-08 2025-03-01 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3235295C (en) 2017-02-20 2024-11-19 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US12215157B2 (en) 2018-02-20 2025-02-04 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
MA53284A (fr) 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
CN116406381A (zh) * 2020-05-19 2023-07-07 希望之城 工程化抗前列腺干细胞抗原融合蛋白及其用途
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2024233662A2 (en) * 2023-05-09 2024-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to psca polypeptides
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032949A2 (en) * 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2281877C (en) * 1997-03-10 2010-01-05 The Regents Of The University Of California Psca: prostate stem cell antigen
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
WO2001040309A2 (en) * 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
KR20120125634A (ko) * 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
RU2381234C2 (ru) * 2004-05-28 2010-02-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками psca
US20120034228A1 (en) * 2008-10-01 2012-02-09 Micromet Ag CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032949A2 (en) * 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Feldmann, A., Stamova, S., Bippes, C.C. et al., The Prostate, 71: 998-1011; 2011. *

Also Published As

Publication number Publication date
EP2726507A1 (de) 2014-05-07
ES2711978T3 (es) 2019-05-08
US20140134155A1 (en) 2014-05-15
SI2726507T1 (sl) 2019-05-31
JP2021121201A (ja) 2021-08-26
RS58448B1 (sr) 2019-04-30
US9200078B2 (en) 2015-12-01
JP6886491B2 (ja) 2021-06-16
HUE042008T2 (hu) 2019-06-28
HRP20190289T1 (hr) 2019-05-03
TR201901991T4 (tr) 2019-03-21
DE102011118022A1 (de) 2013-01-03
CY1121249T1 (el) 2020-05-29
LT2726507T (lt) 2019-04-10
EP3505536A1 (de) 2019-07-03
PL2726507T3 (pl) 2019-06-28
EP2726507B1 (de) 2018-11-21
JP7341185B2 (ja) 2023-09-08
AU2012277784A1 (en) 2014-02-06
JP2019193652A (ja) 2019-11-07
JP2014528696A (ja) 2014-10-30
SMT201900085T1 (it) 2019-05-10
EP3505536B1 (de) 2024-08-07
PT2726507T (pt) 2019-02-26
JP2017104113A (ja) 2017-06-15
JP6549622B2 (ja) 2019-07-24
WO2013001065A1 (de) 2013-01-03
ES2989975T3 (es) 2024-11-28
DK2726507T3 (en) 2019-03-11
EP3505536C0 (de) 2024-08-07
AU2012277784B2 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
DE102011118022B4 (de) Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
JP7605912B2 (ja) Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞
EP2480574B1 (de) Anti-cd33 antikörper und ihre anwendung zum immunotargeting bei der behandlung von cd33-assoziierten erkrankungen
EP2600889B1 (de) Anti-la antikörper und ihre anwendung zum immunotargeting
DE60127143T2 (de) Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
US20220144928A1 (en) Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
KR102749049B1 (ko) 분자를 표적화하기 위한 항원 결합 구조체
DE69909459T2 (de) Cd19xcd3 spezifische polypeptide und deren verwendung
US20080145362A1 (en) Antibody combination useful for tumor therapy
DE102010039019B4 (de) Antikörper gegen 6-sulfo LacNAc positive humane dendritische Zellen und deren Verwendung
DE19744531A1 (de) Bindemoleküle gegen Rezeptor-Ligand-Komplexe
HK1197419B (en) Antibodies against prostate-specific stem cell antigen and use thereof
HK1197419A (en) Antibodies against prostate-specific stem cell antigen and use thereof
HK1255107B (en) Antigen binding constructs to target molecules

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R123 Application deemed withdrawn due to non-payment of filing fee
R409 Internal rectification of the legal status completed
R409 Internal rectification of the legal status completed
R409 Internal rectification of the legal status completed
R082 Change of representative

Representative=s name: KAILUWEIT & UHLEMANN, PATENTANWAELTE, DE

R081 Change of applicant/patentee

Owner name: GEMOAB MONOCLONALS GMBH, DE

Free format text: FORMER OWNER: TECHNISCHE UNIVERSITAET DRESDEN, 01069 DRESDEN, DE

Effective date: 20140318

R082 Change of representative

Representative=s name: KAILUWEIT & UHLEMANN, PATENTANWAELTE, DE

Effective date: 20140318

Representative=s name: KAILUWEIT & UHLEMANN PATENTANWAELTE PARTNERSCH, DE

Effective date: 20140318

R016 Response to examination communication
R018 Grant decision by examination section/examining division
R020 Patent grant now final
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee